These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22655066)

  • 1. Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.
    Remot A; Roux X; Dubuquoy C; Fix J; Bouet S; Moudjou M; Eléouët JF; Riffault S; Petit-Camurdan A
    PLoS One; 2012; 7(5):e37722. PubMed ID: 22655066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with W 80 5EC adjuvanted recombinant RSV rF-ptn enhances clearance of respiratory syncytial virus in a mouse model.
    Passmore C; Makidon PE; O'Konek JJ; Zahn JA; Pannu J; Hamouda T; Bitko V; Myc A; Lukacs NW; Fattom A; Baker JR
    Hum Vaccin Immunother; 2014; 10(3):615-22. PubMed ID: 24326268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease.
    Lindell DM; Morris SB; White MP; Kallal LE; Lundy PK; Hamouda T; Baker JR; Lukacs NW
    PLoS One; 2011; 6(7):e21823. PubMed ID: 21789184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V; Boigard H; Bhatia B; Fallon JT; Alimova A; Gottlieb P; Galarza JM
    Clin Vaccine Immunol; 2016 Jun; 23(6):451-9. PubMed ID: 27030590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.
    Kamphuis T; Stegmann T; Meijerhof T; Wilschut J; de Haan A
    Influenza Other Respir Viruses; 2013 Nov; 7(6):1227-36. PubMed ID: 23575113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
    Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
    Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A unique combination adjuvant modulates immune responses preventing vaccine-enhanced pulmonary histopathology after a single dose vaccination with fusion protein and challenge with respiratory syncytial virus.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Kwon YM; Graham BS; Kang SM
    Virology; 2019 Aug; 534():1-13. PubMed ID: 31163351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with a low-energy electron inactivated respiratory syncytial virus vaccine protects mice without Th2 immune bias.
    Eberlein V; Rosencrantz S; Finkensieper J; Besecke JK; Mansuroglu Y; Kamp JC; Lange F; Dressman J; Schopf S; Hesse C; Thoma M; Fertey J; Ulbert S; Grunwald T
    Front Immunol; 2024; 15():1382318. PubMed ID: 38646538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-27 inhibits vaccine-enhanced pulmonary disease following respiratory syncytial virus infection by regulating cellular memory responses.
    Zeng R; Zhang H; Hai Y; Cui Y; Wei L; Li N; Liu J; Li C; Liu Y
    J Virol; 2012 Apr; 86(8):4505-17. PubMed ID: 22301139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
    Boelen A; Andeweg A; Kwakkel J; Lokhorst W; Bestebroer T; Dormans J; Kimman T
    Vaccine; 2000 Nov; 19(7-8):982-91. PubMed ID: 11115725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection.
    Eichinger KM; Kosanovich JL; Gidwani SV; Zomback A; Lipp MA; Perkins TN; Oury TD; Petrovsky N; Marshall CP; Yondola MA; Empey KM
    Front Immunol; 2020; 11():1673. PubMed ID: 32849580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection.
    van Diepen A; Brand HK; de Waal L; Bijl M; Jong VL; Kuiken T; van Amerongen G; van den Ham HJ; Eijkemans MJ; Osterhaus AD; Hermans PW; Andeweg AC
    J Virol; 2015 May; 89(9):5022-31. PubMed ID: 25694607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipopolysaccharide Inhibits FI-RSV Vaccine-enhanced Inflammation Through Regulating Th Responses.
    Yin W; Li HY; Zheng BY; Deng YQ; Li WJ; Liu Y; Zeng RH
    Curr Med Sci; 2019 Jun; 39(3):363-370. PubMed ID: 31209804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
    Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
    PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Vaccine; 2016 Sep; 34(42):5114-5124. PubMed ID: 27591951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of STAT6 during vaccination with formalin-inactivated RSV prevents induction of Th2-cell-biased airway disease.
    Srinivasa BT; Fixman ED; Ward BJ
    Eur J Immunol; 2014 Aug; 44(8):2349-59. PubMed ID: 24796717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination by microneedle patch with inactivated respiratory syncytial virus and monophosphoryl lipid A enhances the protective efficacy and diminishes inflammatory disease after challenge.
    Park S; Lee Y; Kwon YM; Lee YT; Kim KH; Ko EJ; Jung JH; Song M; Graham B; Prausnitz MR; Kang SM
    PLoS One; 2018; 13(10):e0205071. PubMed ID: 30365561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.